strong>Aerie Pharmaceuticals Inc., of Irvine, Calif., said the FDA has agreed in written and verbal communications that it may change the primary endpoint range of its second phase III registration trial of Rhopressa, named Rocket 2, to include patients with baseline intraocular pressures (IOPs) ranging from above 20 mmHg to below 25 mmHg.